RARE | Page 2 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

35.98

2.56

(256.00%)

content_middle

Previous Close:

33.42

52wk Range:

29.59 - 60.37

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

May 30, 2020 - 9:44am | Out and About, Research Notes, Out and About, Earnings Q1
RegMed/Cell and Gene Therapy Earnings Scorecard - Q1/20 - to date
April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
Regenerative Medicine Earnings Scorecard - Q4 & FY19
November 3, 2019 - 2:45pm | Out and About, Research Notes, Out and About, Earnings
RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector
April 8, 2019 - 11:21am | Out and About, Out and About, Financings
Histogenics (HSGX) reverse mergers with Ocugen, Inc.
March 4, 2019 - 9:28am | Out and About, Research Notes, Out and About
Nightstar Therapeutics (NITE) is being acquired in an all-cash deal ($25.50 per share) by Biogen (BIIB) valuing the U.K gene-therapy company at $877 M
February 26, 2019 - 7:56pm | Out and About, Research Notes, Out and About, Financings
Ultragenyx Pharmaceutical (RARE) prices a 5.072 M share offering at $60.00
January 8, 2019 - 1:13pm | Out and About, Out and About
RegMed Investors’ (RMi) mid-day: sector lost its fire, another I told you so!
October 31, 2018 - 1:29pm | Out and About, Research Notes, Out and About
Intellia Therapeutics (NTLA) delays and pushes back an anticipated trial of its lead gene editing treatment
October 10, 2018 - 8:43pm | Out and About, Research Notes, Out and About, Financings
Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00
September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
June 18, 2018 - 9:34am | Out and About, Research Notes, Out and About
Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment
June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
Regenerative Medicine Earnings Scorecard - Q1/18 - to date
June 12, 2017 - 8:59am | Research Notes
Fibrocell Science (FCSC) gets “Rare Pediatric Disease Designation” from FDA
January 11, 2017 - 8:29am | Research Notes
Sangamo Therapeutics (SGMO) orphan drug designation to SB-318
June 29, 2016 - 8:59am | Research Notes
Biostage (BSTG) Files for FDA Orphan Drug Designation
May 17, 2016 - 10:18am | BOD & C-Suite Updates
Intrexon (XON), Fate (FATE), Kite (KITE) – Changes in the C-Suites
May 12, 2016 - 11:14am | Research Notes, Henry'omics
Avalanche Biotechnologies (AAVL) acquires Annapurna Therapeutics - combined company renamed Adverum Biotechnologies with a new symbol ADVM
May 5, 2016 - 10:20am | Henry'omics, Regulatory
Applied Genetic Technologies (AGTC) Researchers reported that expression of therapy-derived AAT is present at steady levels in the serum and injected muscle five years after dosing.
March 22, 2016 - 12:27pm | Henry'omics, Out and About
uniQure (QURE) Pre-clinical data supports Huntington's disease gene therapy program
February 29, 2016 - 2:51pm | Henry'omics, BOD & C-Suite Updates
BioTime (NYSEMKT: BTX) subsidiary Asterias Biotherapeutics (NYSEMKT: AST) New CEO and board member

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.